Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Fox

Showing results (51-60 of 186) with videos related to

Pageof 19
Sort By:
The American Surgeon|May 23, 2024
Establishing Geriatric Opiate Use Patterns in TraumaEmily Hammond, Samantha Zhan-Moodie, Viktoriya Sapkalova, et al.
Cancer Chemotherapy and Pharmacology|July 10, 2019
Population pharmacokinetics of trabectedin in adolescent patients with cancerItalo Poggesi, Belén Valenzuela, Daniele Ouellet, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2021
A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcomaElizabeth Fox, Christine Busch, Alexander DeBernardo, et al.
Pediatric Blood & Cancer|January 3, 2018
Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)Robin E Norris, Elizabeth Fox, Joel M Reid, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2015
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumorsElizabeth Fox, Brigitte C Widemann, Devang Pastakia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumorsKatherine E Warren, Alberta A Aikin, Madeleine Libucha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory DecisionsBram De Wilde, Elly Barry, Elizabeth Fox, et al.
Pediatric Blood & Cancer|October 16, 2019
The ganglioside G<sub>D2</sub> as a circulating tumor biomarker for neuroblastomaFrank Milton Balis, Christine Maria Busch, Ami Vijay Desai, et al.
Pediatric Blood & Cancer|August 1, 2012
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumorsMeredith K Chuk, Alberta Aikin, Trish Whitcomb, et al.
Cancer Chemotherapy and Pharmacology|December 30, 2016
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot ConsortiumFrank M Balis, Patrick A Thompson, Yael P Mosse, et al.
Pageof 19

Showing results (51-60 of 186) with videos related to

Sort By:
Pageof 19
The American Surgeon|May 23, 2024
Establishing Geriatric Opiate Use Patterns in TraumaEmily Hammond, Samantha Zhan-Moodie, Viktoriya Sapkalova, et al.
Cancer Chemotherapy and Pharmacology|July 10, 2019
Population pharmacokinetics of trabectedin in adolescent patients with cancerItalo Poggesi, Belén Valenzuela, Daniele Ouellet, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2021
A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcomaElizabeth Fox, Christine Busch, Alexander DeBernardo, et al.
Pediatric Blood & Cancer|January 3, 2018
Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)Robin E Norris, Elizabeth Fox, Joel M Reid, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2015
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumorsElizabeth Fox, Brigitte C Widemann, Devang Pastakia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumorsKatherine E Warren, Alberta A Aikin, Madeleine Libucha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory DecisionsBram De Wilde, Elly Barry, Elizabeth Fox, et al.
Pediatric Blood & Cancer|October 16, 2019
The ganglioside G<sub>D2</sub> as a circulating tumor biomarker for neuroblastomaFrank Milton Balis, Christine Maria Busch, Ami Vijay Desai, et al.
Pediatric Blood & Cancer|August 1, 2012
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumorsMeredith K Chuk, Alberta Aikin, Trish Whitcomb, et al.
Cancer Chemotherapy and Pharmacology|December 30, 2016
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot ConsortiumFrank M Balis, Patrick A Thompson, Yael P Mosse, et al.
Pageof 19